Information services provider Thomson Reuters, US, has announced that the Medical Research Commercialisation Fund (MRCF) has chosen Thomson Pharma, to serve the key commercialisation and business development needs of its 27 members. Thomson Pharma claims to be the largest and most comprehensive database of critical pharmaceutical market intelligence. It is widely used by clinical researchers, competitive intelligence analysts, business development professionals and brand management employees, globally.
The MRCF has facilitated individual subscriptions to Thomson Pharma for its member organisations, providing them with access to critical pipeline and competitor knowledge to help them optimise their product portfolio, monitor industry developments and make informed investment decisions. Members of MRCF can find relevant data integrated from more than 40 pharmaceutical data sources placed in context with unique abstracts, commentaries and analysis prepared by Thomson Reuters industry experts.
Thomson Pharma covers the entire competitor intelligence needs of pharmaceutical innovators. This includes information on the latest drugs, compounds, genetic sequences and targets, clinical trials and licensing opportunities, patents, journals, conferences, academic articles and more.
earch for more Reference Tools
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
